TREATING RELAPSE WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN AND AMANTADIN FOR EITHER 72 OR 48 WEEKS (IN PATIENTS WITH HCV-TYPE 1/3 INFECTION): RESULTS FROM THE TRELA-STUDY

Buggisch, P. and Zeuzem, S. and Teuber, G. and Moeller, B. and Ehrhardt, A. and Gelbmann, C. and Encke, J. and Pohle, T. and Manns, M. P. and Stoll, S. and Berg, T. (2009) TREATING RELAPSE WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN AND AMANTADIN FOR EITHER 72 OR 48 WEEKS (IN PATIENTS WITH HCV-TYPE 1/3 INFECTION): RESULTS FROM THE TRELA-STUDY. In: 44th Annual Meeting of the European Association for the Study of the Liver, April 22-26, 2009, Copenhagen, Denmark.

Full text not available from this repository. (Request a copy)
Item Type: Conference or Workshop Item (Poster)
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin I
Depositing User: Petra Gürster
Date Deposited: 27 Oct 2022 04:53
Last Modified: 27 Oct 2022 04:53
URI: https://pred.uni-regensburg.de/id/eprint/29765

Actions (login required)

View Item View Item